MDGL Madrigal Pharmaceuticals Inc

Price (delayed)

$122.80

Market cap

$1.9B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$11.07

Enterprise value

$1.79B

Sector: Healthcare
Industry: Biotechnology

Highlights

The company's net income has shrunk by 152% YoY and by 27% QoQ
The EPS has plunged by 151% YoY and by 27% from the previous quarter

Key stats

What are the main financial stats of MDGL
Market
Shares outstanding
15.47M
Market cap
$1.9B
Enterprise value
$1.79B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.54
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$170.86M
EBITDA
-$170.48M
Free cash flow
-$115.35M
Per share
EPS
-$11.07
Free cash flow per share
-$7.47
Book value per share
$18.77
Revenue per share
$0
TBVPS
$21.98
Balance sheet
Total assets
$339.62M
Total liabilities
$49.91M
Debt
$863,000
Equity
$289.7M
Working capital
$288.24M
Liquidity
Debt to equity
0
Current ratio
6.84
Quick ratio
6.81
Net debt/EBITDA
0.64
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-43.2%
Return on equity
-47.6%
Return on invested capital
-59.2%
Return on capital employed
-58.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MDGL stock price

How has the Madrigal Pharmaceuticals stock price performed over time
Intraday
2.17%
1 week
0.81%
1 month
5%
1 year
38.4%
YTD
10.46%
QTD
10.46%

Financial performance

How have Madrigal Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$177.07M
Net income
-$170.86M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 152% YoY and by 27% QoQ
MDGL's operating income has shrunk by 123% YoY and by 24% QoQ

Growth

What is Madrigal Pharmaceuticals's growth rate over time

Valuation

What is Madrigal Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.54
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 151% YoY and by 27% from the previous quarter
The stock's price to book (P/B) is 49% more than its last 4 quarters average of 4.4 and 39% more than its 5-year quarterly average of 4.7
The equity is down by 34% year-on-year and by 16% since the previous quarter

Efficiency

How efficient is Madrigal Pharmaceuticals business performance
Madrigal Pharmaceuticals's ROIC has decreased by 46% from the previous quarter
The ROE has contracted by 40% from the previous quarter
MDGL's return on assets is down by 37% since the previous quarter

Dividends

What is MDGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MDGL.

Financial health

How did Madrigal Pharmaceuticals financials performed over time
The company's quick ratio has shrunk by 77% YoY and by 20% QoQ
The current ratio has dropped by 77% year-on-year and by 20% since the previous quarter
The debt is 100% smaller than the equity
The debt has surged by 66% since the previous quarter and by 15% year-on-year
The equity is down by 34% year-on-year and by 16% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.